Multiple Myeloma: all 3,713 studies

Page 16 of 38. Open to participants first (754), then studies with results posted, then the rest; newest registration first within each.

• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
• Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00536575Phase 1/2Results posted
• Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell TransplantCompletedNCT00534118Not applicableResults posted
• A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple MyelomaCompletedNCT00531453Phase 2Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Phase 2 Study of Carfilzomib in Relapsed Multiple MyelomaCompletedNCT00530816Phase 2Results posted
• Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow TransplantCompletedNCT00530218Phase 2Results posted
• Dalteparin in Preventing DVT in Participants With CancerCompletedNCT00525057Not applicableResults posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple MyelomaCompletedNCT00523848Phase 2Results posted
• Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With DexamethasoneTerminatedNCT00522392Phase 3Results posted
• Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition DiseaseCompletedNCT00520767Phase 2Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With CancerCompletedNCT00516503Phase 3Results posted
• Sunitinib in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00514137Phase 2Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple MyelomaCompletedNCT00511238Phase 2Results posted
• Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma PatientsCompletedNCT00507442Phase 1/2Results posted
• Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneCompletedNCT00507416Phase 3Results posted
• FM 140 vs FM100 Study in Patients With Multiple MyelomaCompletedNCT00505895Phase 2Results posted
• Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple MyelomaCompletedNCT00483262Phase 1/2Results posted
• A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00478777Phase 3Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00478218Phase 2Results posted
• Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00477971Phase 3Results posted
• Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00477750Phase 1/2Results posted
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
• A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)CompletedNCT00473590Phase 2Results posted
• Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple MyelomaTerminatedNCT00470093Early Phase 1Results posted
• Velcade, Trisenox, Vitamin C and Melphalan for Myeloma PatientsCompletedNCT00469209Phase 1/2Results posted
• A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00464178Phase 2Results posted
• Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT00461045Phase 2Results posted
• Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic AmyloidosisCompletedNCT00458822Phase 2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple MyelomaCompletedNCT00458705Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseasesCompletedNCT00453206Not applicableResults posted
• Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00450814Phase 1/2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseCompletedNCT00448201Phase 2Results posted
• Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple MyelomaCompletedNCT00445692Phase 2Results posted
• Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00445484Phase 2Results posted
• Efficacy and Safety of LBH589B in Adult Patients With Multiple MyelomaTerminatedNCT00445068Phase 2Results posted
• Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple MyelomaTerminatedNCT00441168Phase 2Results posted
• Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple MyelomaCompletedNCT00439465Phase 2Results posted
• Aflibercept for Relapsed Multiple MyelomaTerminatedNCT00437034Phase 2Results posted
• A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple MyelomaCompletedNCT00434161Phase 3Results posted
• Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple MyelomaCompletedNCT00432458Phase 3Results posted
• A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple MyelomaCompletedNCT00429949Phase 2Results posted
• Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple MyelomaCompletedNCT00427765Phase 2Results posted
• Cellular Therapy With Cord Blood CellsCompletedNCT00427557Phase 2Results posted
• A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00424047Phase 3Results posted
• A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00420849Phase 3Results posted
• Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by ChemotherapyCompletedNCT00416624Phase 2Results posted
• Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple MyelomaCompletedNCT00410605Phase 2Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.CompletedNCT00405756Phase 3Results posted
• A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00401843Phase 2Results posted
• Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple MyelomaCompletedNCT00400686Not applicableResults posted
• Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem CellsCompletedNCT00398411Phase 3Results posted
• Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for TransplantationTerminatedNCT00396383Phase 2Results posted
• AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSFCompletedNCT00396266Phase 2Results posted
• AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF AloneTerminatedNCT00395967Phase 2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT00378209Phase 2Results posted
• Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00378105Phase 1/2Results posted
• Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple MyelomaTerminatedNCT00366106Phase 2Results posted
• High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple MyelomaCompletedNCT00349778Phase 2Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.CompletedNCT00330759Phase 3Results posted
• Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.CompletedNCT00325416Phase 1/2Results posted
• Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322842Phase 2Results posted
• Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322491Phase 2Results posted
• Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma PatientsCompletedNCT00322387Phase 2Results posted
• Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• Allogeneic Bone Marrow Transplantation Using Less Intensive TherapyTerminatedNCT00303719Phase 2Results posted
• Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantCompletedNCT00293384Not applicableResults posted
• Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple MyelomaCompletedNCT00287872Phase 2Results posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Study of Immune Response Modifier in the Treatment of Hematologic MalignanciesTerminatedNCT00276159Phase 2Results posted
• A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow TransplantationTerminatedNCT00275262Phase 2Results posted
• Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - DenosumabCompletedNCT00259740Phase 2Results posted
• Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple MyelomaCompletedNCT00258206Phase 2Results posted
• MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous TransplantationTerminatedNCT00256776Phase 3Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic CancerTerminatedNCT00255684Not applicableResults posted
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple MyelomaTerminatedNCT00240162Phase 2Results posted
• A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple MyelomaCompletedNCT00229203Phase 2Results posted
• A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of LifeCompletedNCT00222105Phase 2Results posted
• Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple MyelomaCompletedNCT00217438Phase 3Results posted
• Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)TerminatedNCT00215943Phase 3Results posted
• Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple MyelomaCompletedNCT00185614Phase 2Results posted
• Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple MyelomaCompletedNCT00179647Phase 3Results posted
• Autologous Transplant for Multiple MyelomaCompletedNCT00177047Phase 2/3Results posted
• Stem Cell Transplant for Hematological MalignancyTerminatedNCT00176930Not applicableResults posted
• Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage ITerminatedNCT00171925Phase 3Results posted
• Post Transplant Donor Lymphocyte InfusionTerminatedNCT00167180Phase 2Results posted
• Bortezomib (Velcade) in Patients With Untreated Multiple MyelomaCompletedNCT00153920Phase 2Results posted
• Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological MalignanciesCompletedNCT00150462Phase 1Results posted
• Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple MyelomaCompletedNCT00148317Phase 2Results posted
• Study of Low-Intensity Conditioning for Allogeneic Stem Cell TransplantCompletedNCT00143845Phase 2Results posted
• Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple MyelomaCompletedNCT00135200Phase 2Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted

← Multiple Myeloma overview